[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-348994-105":59,"doc-detail-348994-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","international-neuroblastoma-risk-group-consortium-a-model-of-networking-for-rare-cancers","International neuroblastoma risk group consortium - a model of networking for rare cancers","","Sharing knowledge and harmonizing approaches is critical to accelerate rare cancer progress. In 2004, the International Neuroblastoma Risk Group (INRG) Task Force was established by four major neuroblastoma cooperative groups to meet this objective. Neuroblastoma strategies became a reference for other rare malignancies. An initial cohort of 8,800 patients was transferred to the INRG Data Commons, enabling a data-sharing model. Information on 25,000+ patients now supports harmonized staging, risk classification, and consensus criteria for biological data, disease extent, and treatment response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/international-neuroblastoma-risk-group-consortium-a-model-of-networking-for-rare-cancers/348994/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/international-neuroblastoma-risk-group-consortium-a-model-of-networking-for-rare-cancers/348994.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of forming the INRG Task Force?","Question",{"text":112,"@type":113},"The INRG Task Force was created to share knowledge and harmonize approaches to optimize progress in rare cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was patient data shared in the INRG model?",{"text":117,"@type":113},"Data from an initial cohort of 8,800 patients was transferred to the INRG Data Commons, where a data-sharing model was developed.",{"name":119,"@type":110,"acceptedAnswer":120},"What impact have INRG staging and risk classification systems had?",{"text":121,"@type":113},"They have enabled harmonized therapeutic groupings and uniform criteria for classifying biological data, evaluating disease extent, and defining treatment response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},348994,1790161902,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","JNCI: Journal of the National Cancer Institute, 2026, 118(4), 579–588  \n[https://doi.org/10.1093/jnci/djaf242](https://doi.org/10.1093/jnci/djaf242)  \nAdvance Access Publication Date: August 25, 2025  \nCommentary  \nInternational neuroblastoma risk group consortium: a model of networking for rare cancers  \nSusan L. Cohn , MD1,‡, Wendy B. London , PhD2,‡, Gudrun Schleiermacher , MD, PhD3, Lucas Moreno , MD, PhD4, Inge M. Ambros , PhD5, Peter F. Ambros , PhD6, Rochelle Bagatell , MD7,8, Maja Beck Popovic , MD9,  \nKlaus Hermann Beiske , MD, PhD10, 11, Frank Berthold , MD12, Suzi Birz , MScMI13, HervJ. Brisse , MD14,  \nGarrett M. Brodeur , MD7,8, Penelope R. Brock , MD15, Susan Burchill, PhD16, Angelika Eggert, MD17, 18, Sara M. Federico, MD19, Matthias Fischer , PhD20, Brian T. Furner , MS13, Barbara Hero , MD21, David Machin, PhD22, Takehiko Kamijo , MD23, Katherine K. Matthay , MD24, Akira Nakagawara , MD, PhD25, Arlene Naranjo , PhD26, Ulrike P€otschger , PhD27, Dominique Valteau-Couanet, MD28, Michael T. Watkins , PhD13, Meredith S. Irwin , MD29,  \nSamuel L. Volchenboum , MD, PhD13, Julie R. Park , MD19, Andrew D.J. Pearson , MD30, 􀀃 1Department of Pediatrics, Comer Children’s Hospital and University of Chicago, Chicago, IL, United States  \n2Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Division of Hematology and Oncology, Department of Pediatrics, Harvard Medical School, Boston, MA, United States  \n3SIREDO Integrated Pediatric Oncology Center and U1330 Institut national de la sant et de la recherche mdicale (INSERM), Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France  \n4Department of Pediatric Oncology, Vall d’Hebron Hospital, Barcelona, Spain 5Children’s Cancer Research Institute, Vienna, Austria (retired)  \n6Children’s Cancer Research Institut, Vienna, Austria (emeritus)  \n7Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States 9Faculty of Biology and Medicine, University Hospital CHUV, Lausanne, Switzerland 10Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway 11Department of Pathology, Oslo University Hospital Radiumhospitalet, Oslo, Norway  \n12Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany (retired) 13Department of Pediatrics, Data for the Common Good, University of Chicago, Chicago, IL, United States 14Imaging Department, Institut Curie and Universit Paris Sciences et Lettres, Paris, France  \n15Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom (retired) 16Children’s Cancer Research Group, Leeds Institute of Medical Research, St James’s University Hospital, Leeds, United Kingdom 17Department of Pediatric Oncology/Hematology, Charit -Universit€atsmedizin, Berlin, Germany  \n18German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany 19Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, United States  \n20Department of Experimental Pediatric Oncology, University Children’s Hospital, Medical Faculty, Center for Molecular Medicine Cologne, University of Cologne, Germany  \n21Department of Pediatric Oncology and Hematology, University Children’s Hospital, Medical Faculty University of Cologne, K€oln, Germany 22University of Leicester, United Kingdom (retired)  \n23Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan  \n24Department of Pediatrics, University of California San Francisco (UCSF) School of Medicine and UCSF Benioff Children’s Hospital, San Francisco, CA, United States  \n25Saga International Carbon Particle Beam Radiation Cancer Therapy Center, Saga HIMAT Foundation, Saga, Japan  \n26Department of Biostatistics, University of Florida Children’s Oncology Group Statistics and Data Center, Gaine","cbCaisUgLigN2Lxd","https://ap.wps.com/l/cbCaisUgLigN2Lxd","pdf",1107516,11,"English","# Abstract\n## Author contributions\n## Corresponding author\n## Publication and access information","[{\"question\":\"What was the purpose of forming the INRG Task Force?\",\"answer\":\"The INRG Task Force was created to share knowledge and harmonize approaches to optimize progress in rare cancers.\"},{\"question\":\"How was patient data shared in the INRG model?\",\"answer\":\"Data from an initial cohort of 8,800 patients was transferred to the INRG Data Commons, where a data-sharing model was developed.\"},{\"question\":\"What impact have INRG staging and risk classification systems had?\",\"answer\":\"They have enabled harmonized therapeutic groupings and uniform criteria for classifying biological data, evaluating disease extent, and defining treatment response.\"}]","International neuroblastoma risk group consortium - a model of networking for rare cancers | PDF",1790081075,28]